PRIFTIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Priftin, and what generic alternatives are available?
Priftin is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in PRIFTIN is rifapentine. Three suppliers are listed for this compound. Additional details are available on the rifapentine profile page.
Summary for PRIFTIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 33 |
Clinical Trials: | 11 |
Patent Applications: | 2,988 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for PRIFTIN |
What excipients (inactive ingredients) are in PRIFTIN? | PRIFTIN excipients list |
DailyMed Link: | PRIFTIN at DailyMed |
Recent Clinical Trials for PRIFTIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Taipei Veterans General Hospital, Taiwan | Phase 3 |
Centers for Disease Control, Taiwan | Phase 3 |
National Taiwan University | Phase 3 |
Pharmacology for PRIFTIN
Drug Class | Rifamycin Antimycobacterial |
Anatomical Therapeutic Chemical (ATC) Classes for PRIFTIN
US Patents and Regulatory Information for PRIFTIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | PRIFTIN | rifapentine | TABLET;ORAL | 021024-001 | Jun 22, 1998 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |